Welcome by the news that Abcam has just
We never tire of listening to great
been announced as the AIM
champions for the sector. We were
Company of the Year. Huge
honoured and humbled that we
congratulations to the Abcam
had a brace of Sirs to open our
inaugural ON Helix Conference in the Summer where the champions
There has been one heck of a lot
were out in force! Sir William
going on since our Spring
Castell, Chair of the Wellcome
Newsletter. Not least the
Trust and Sir Mike Rawlins – what
Government’s £185 million of
a double-act they were and so full
additional funding for the
of praise for the event with Sir
Technology Strategy Board,
Mike saying it ‘was a great day
announced in the Spending Review with a fantastic line up – showing in the Summer, against a backdrop the importance of addressing of billions of pounds of cuts from
translational research topics and a
public finances. The continuation of great showcase for the strength of the Biomedical Catalyst Fund in
biomedical innovation’. He added
particular is great for the life
that it was ‘THE event in the UK
A very warm One Nucleus welcome science and healthcare sector. And where all participants can network to our Autumn Newsletter.
we read with great interest here
at the highest level and learn an
the new HM Government Industrial incredible amount’. With feedback It’s always great bringing the
Strategy for Agricultural Science,
from delegates equally fulsome,
newsletter together and this last 6
Technology and Innovation – an
we shall have it as an annual event
months has been especially
important statement of support for for sure (do put 2 July 2014,
exciting. The following pages are
the agri-food sector and of huge
Churchill College, Cambridge in
jam-packed with glowing
benefit to a number of our
your diaries). Read all about it on
testimonies to the hard work,
members located in the East of
Page 22 and check out one of the
fantastic research, innovation and
England in particular where agri-
best photos from the One Nucleus
commercialisation that our
innovation is a major part of the
back library this year!
members put their hearts and
minds to on a daily basis. This was
(Continued on page 2)
exemplified beautifully this week
A Meeting of Minds at Genesis that Led to Neuro-Bio Ltd
Connecting with the NHS
Insight into the Newly Formed AHSNs
31 Partnership A New NonCommercial Partnership
he is an uplifting tour de force and certainly a champion for the
Our new ‘Ask One Nucleus’ service
sector. Did Charles Darwin come
that we launched earlier this year
from Bromley as he claimed? Who has proved to be extremely knows? But the point is that he
popular. Critical intelligence for
our members when they want it, from specialist advisers at the
Meanwhile, we have fixed the
touch of a button. Our fresh new
dates for all our other events for
website home page clearly shows
2014 - and will (as usual) be
how to access this Dashboard of
running an event in London and
support. We have recently added
Cambridge every month (with the
to the list of services with
exception of August). At the
‘International Business’. I am
moment many of the One Nucleus often asked what is different Here at One Nucleus we are
team have their eyes fixed on 12
about One Nucleus and a
always ready with our praise for
December and our annual Genesis favourite response of mine is to
others (where due) and always
Conference. To get a feel for how
say that we believe we are the
have a positive outlook on the
it is developing this year, read
most connected membership
sector and life generally! There
more on Page 30. We shall be
organisation in the world – the
are several highlights of recent
bringing back the hugely popular
‘Nucleus’ even! That is no small
months I’d like to note. We were
One Nucleus/Scrip debate (started claim. But when I list the
delighted to be a Partner with the
last year) and are getting very
relationships that we have around
Judge Business School/Centre for
excited about our new Talent
the globe – from those with our
Entrepreneurial Learning and
Lounge. We shall launch our Wall
US counterparts (MassBIO,
great One Nucleus member
Planner 2014 at Genesis (which
Biocom etc) and across Europe,
Miranda Weston-Smith for their
will give the dates for our events
and in the UK, it is a long and
‘Beating the Odds’ Conference
next year and other key ones that quality list. The International
that took place this month. What
our members attend). There are
Business tab on the Dashboard is
an inspiring day that was –
still a couple of sponsor
the first port of call if you would
uplifting stories about meeting the opportunities with it so do contact like us to connect you to pretty sectors challenges head-on, with
email@example.com if you
a clear focus on strong
would like your company to be
management and even stronger
featured on the Wall Planner.
innovation. Other collaborators have had great news too – OBR and SROne have announced that the OneStart competition which I was so pleased to be involved in this year will be taking place again next year and anyone who was at the BIA’s event at the Royal College of Surgeons last week must surely still be reeling from the Mayor of London, Boris Johnson’s speech – whether you agree with that gentleman’s politics or not, there is no doubt
much any market in the world. (Continued on page 3)
collaboration which is hot off the
between the two organisations!
press and the ink not yet dried with… Nature. We welcome them I hope you enjoy our Autumn into the fold and are looking
Newsletter. It showcases a
forward very much to working
fabulous cross section of our
with them for mutual (and in our
members and highlights what we
case ‘Member’ benefit).
at One Nucleus are up to and what we are about as a team. If
At One Nucleus we never rest on
you have any thoughts,
Our spirit of collaboration is
our laurels and are always
comments or would like to be
immense, which along with
scrutinising our member ‘offer’ to
involved in a future edition (they
quality service to our members is
do all we can to ensure it is fit for are Spring and Autumn each
at the heart of what we do. In the member purpose. With that in
year), do drop me a line at
coming months do watch out for
mind I’m delighted to formally
news on the plans we have with a launch here our ‘ON Hub’ service range of partners – from the work – your global home from home we are doing with the BIA,
on Page 34. Mindful that many of
Bionow and BioPartner to create a you/us are on the move a lot of LifeScience Manifesto in advance
the time, this service enables ON
of the next election (download
Hub card holders to access great
the flyer here http://
facilities around the UK to
conduct their business meetings –
somewhere to use WiFi and
through to our hosting of our
business services, have a coffee
annual Dinner at BIO with a
and have meetings from
range of overseas companies.
Cambridge to Wales to London to
Additionally our Partner
over 100 other locations around
Programme is developing every
the UK. Additionally do check out
day – and I’m delighted to
our new ON Insights initiative on
announce for the first time here
that we have a brand new And finally, I have a couple of ‘goodbyes’ – to Philip (Kendall) in the team who returned to the Foreign Office in August to study Korean. Philip was on a sabbatical from the FCO so we always knew the day would come and wish him every success for his new challenge! And of course a fond farewell to Ollie (Muncey) who has joined the BIA. When he told me I said I thought it was a great next step for him on his career path and added that it was quite a ‘significant’ way of cementing the close working relationship
CEO One Nucleus
A Meeting of Minds That Led to Neuro-Bio Ltd Sometimes a chance meeting can change your whole outlook, and indeed your entire plans and prospects for the future. This is what happened when entrepreneur Nathan Nagel and neuroscientist Baroness Professor Greenfield met for the first time at the One Nucleus Genesis Conference at the QE II Conference Centre in December 2012.
Baroness Professor Susan Greenfield and Nathan Nagel
Move forward nine months and the whole team has assembled to create Neuro-Bio, a spin-out company from Oxford University funded by HNWi. Based at the London Bioscience Innovation Centre, the team comprises Professor Susan Greenfield (Chief Scientific Officer), Nathan Nagel (Chief Executive Officer), Dr Graham Bell (Chief Operations Officer) alongside Dr Gwenael Pottiez, Dr Sara Garcia Ratés, Emily Smith, Scott Badin, John Burchill, Anthony Clayden, Dr Nigel Toseland and Dr Scott Kahn.
One Nucleus spoke to Professor Greenfield on her and Nathan’s joint venture, the neuroscience biotechnology drug and biomarker company Neuro-Bio Ltd. ‘Ours is a story worth telling’ explains Professor Greenfield, ‘it illustrates how, by combining private sector expertise with pure academic research, significant progress can be achieved that neither group could have realised unilaterally. Ultimately, although diametrically opposed in culture, the yin and yang of academia and commerce need each other like left and right. There is of course a plethora of biotech and world leading science in the UK but what makes the difference?’ ‘Although culturally different Nathan and I found we share core
‘The first barrier is always getting a good idea off the ground within the typically risk-averse university environment,’ says Professor Greenfield. ‘I have had my own values, ethics, beliefs and we both experiences of manning the bring a strong determined approach barricades against a scientific to life and work. We asked ancien regime. I believed in the ourselves “how far can we take somewhat bizarre possibility that a this” and with personalities such as very familiar enzyme, ours we quickly agreed on “all the acetylcholinesterase (AChE) might way and nothing will stop us from have a second job as well, an alter achieving the shared vision”. We ego that has nothing to do with strongly believe it is these being an enzyme. In my lab I had intangible factors that form the been pioneering the tantalising cohesive bonds that transform a company into a team.’ (Continued on page 4)
‘The yin and yang of academia and commerce need each other like left and right.’ Baroness Professor Susan Greenfield
‘We can move towards eradicating the globally shared fear of looking in the mirror and not knowing who is looking back.’ Baroness Professor Susan Greenfield possibility that perhaps a crucial fragment of this molecule breaks away to play a pivotal role in the as yet unidentified mechanism underlying neurodegenerative disorders such as Parkinson’s and Alzheimer’s.’
Greenfield. ‘Dr Marshall was snubbed by his peers and ignored by investors until of course he proved the big companies wrong and changed the way the world looks at peptic ulcers. As our data accumulates I hope that in the future others may appreciate my firm conviction that the “popular” beta amyloid theory does not accurately tell the whole story behind neurodegeneration.’
‘There has been no new drug introduced to combat Alzheimer’s disease specifically, or neurodegeneration more generally, in the last 15 years. The reason is that as yet, there is no accepted or It may have resulted from a leap of proven basic mechanism that could faith following a chance meeting at consequently be targeted pharmaceutically. The “cholinergic hypothesis” posits that the key issue is a deficit of acetylcholine, due to death of cholinergic neurons. Despite the popularity of amyloid formation as a pharmaceutical target over the last two decades, no treatment based on this theory has as yet proved effective’. Yet time and again Greenfield says her application to public sector funding bodies inevitably met with the same continuing rebuttal, ‘interesting’ but ‘no, as it’s too speculative’. Luckily however, Greenfield’s lab managed to zig-zig slowly forward, thanks to sheer determination and to modest philanthropic funding from the USA. ‘I’m not alone in following what I know to be true, irrespective of prevailing dogma. In recent years scientists such as Dr Barry Marshall also dared to challenge accepted wisdom,’ continues Professor
potential to create a simple diagnostic kit to test for Alzheimer’s. Through therapeutics and diagnostics, Neuro-Bio firmly believes that by supporting and empowering patients every step of the way, we can move towards eradicating the globally shared fear of looking in the mirror and not knowing who is looking back.’ Professor Greenfield concludes ‘as a company Neuro-Bio will no doubt have both supporters and critics: but through radical new thinking of the problem, the team of academia and commerce can work towards a goal that neither of us could have developed unilaterally.’ All questions to firstname.lastname@example.org. The official launch of the company Neuro-Bio, and its website and vision, will be held at the Royal Institute, www.rigb.org, on the 17 October.
‘The first barrier is always getting a good idea off the ground within the typically risk-averse university environment,’ Baroness Professor Susan Greenfield
Genesis, but the team hopes the formation of Neuro-Bio means that an additional avenue of hope will open to people who fear Alzheimer’s in the future. ‘Although the company is working as fast as possible, the prospect of moving from a molecule to a market ready therapeutic is realistically still 12 to 14 years away. Recognising that accurate diagnostics are equally important, Neuro-Bio is also developing a biomarker with the
Connecting with the NHS Professor Sir Michael Rawlins gave One Nucleus an insight into the newly formed Academic Health Science Networks (AHSNs) and his plans for the Eastern network (EAHSN) where he has recently been appointed as Chair.
Sir Mike Rawlins, Chair of the Eastern AHSN
In May this year, the formation of Academic Health Science Networks was announced by NHS England. What is the rationale behind these new organisations? ‘The idea of Academic Health Science Networks was first introduced by Sir David Nicholson in his report “Innovation, Health and Wealth” published in late 2011. As he stated in the report, “by working with stakeholders from across the NHS and scientific community, academia, the third sector and local authorities, the AHSNs will link up the system and drive up diffusion of innovation”.’ ‘The stimulus for creating AHSNs was the recognition that the participants in the development and dissemination of innovative products and processes for healthcare were fragmented. The AHSNs are therefore intended to bring the participants together to improve the health of the population as a whole; and at the same time provide support for the
life sciences in developing innovative new products.’
innovative and cost effective products than hitherto.'
‘The Eastern Regional Academic Health Science Network (EAHSN) has been established in this style. Its business plan is just about to be signed off and partners will soon see the EAHSN commence programmes of work that will embed innovation and best practice into all our clinical, industrial and research based activities.’
How will you encourage creative thinking and harness bright ideas generated in your region before translating them into measurably improved patient outcomes?
Dame Sally Davies, NHS England's Chief Medical Officer, has said ‘The AHSNs provide an important mechanism for achieving a step-change in the way the NHS translates research, innovation and best practice into effective and costeffective treatments and services for patients’. How will AHSNs succeed in transforming healthcare where arguably others have been less successful in making significant change happen?
‘The EAHSN has ambitious plans. Here are just two of the various projects being rolled out.’ ‘To encourage clinical research in the NHS we want to move away from the current situation whereby each Trust agrees individually the arrangements for a particular study. Instead, we want to develop an arrangement for a “single signoff” with one Trust acting on behalf of the others.’ ‘At the present each NHS hospital has its own unique prescription chart. As a consequence new medical and nursing staff must negotiate their way around an unfamiliar document with, for
‘The NHS needs to be swifter in adopting new, innovative and cost effective products than hitherto.' Professor Sir Michael Rawlins Chair of the Eastern AHSN (Academic Health Science Network) ‘We need to build on the success of the National Institute for Health Research that Dame Sally has so ably created. The NHS needs to be more accessible and speedier in setting up clinical trials. But equally important, and some might say more important, the NHS needs to be swifter in adopting new,
example, information about drug allergies in a different position from the chart in their previous hospitals. This can lead to errors in both prescribing and administration of medicines. We want to develop and introduce a single inpatient prescription chart, across the (Continued on page 7)
network, to improve the safety of patients.’
‘Each of these companies has been supported by the SBRI programme. As a result they are developing SBRI Healthcare is a project innovative products and, at the One Nucleus members read same time, growing successful about in the Spring newsletter businesses. The EAHSN has could you update us? recently launched a whole new set ‘The Small Business Research of SBRI competitions - so I would Initiative (SBRI) is a crossurge companies in the One Nucleus government programme, with the family to look on the website Eastern AHSN now running the www.sbrihealthcare.co.uk and healthcare part. The programme come forward with their ideas.’ provides funding to companies for the development of ideas to meet a known need. It is challenge led with the NHS outlining its needs and inviting companies to offer solutions on a competitive basis. The SBRI programme funds up to £100k for the first phase of development (focusing on feasibility and proof of concept) and then, providing there is a positive outcome, up to £750k per project is available for the second – development – phase.’
enables us to make a step change in our relations with business. We are planning an ambitious programme that seeks to support wealth creation as well as leading edge practice in clinical care.’ How do you envisage EAHSN working with other membership networks in the region such as One Nucleus and how can our members contribute (and benefit) from a close link?
‘Organisations such as One Nucleus play a critical role in helping establish effective links with the life science industry’. Professor Sir Michael Rawlins Chair of the Eastern AHSN (Academic Health Science Network)
‘The SBRI Programme has been run from the Eastern region since 2009. During that time we have had over 700 applications, of which 66 have been funded to phase one level and 31 have secured phase two funding. From this £17.6m investment we have seen companies develop products that are already being used in patient care. For example:
Fundamental to success would appear to be strong collaboration on many levels within EAHSN and across the 14 other AHSNs, with industry, academia, other research organisations, etc. With this is mind, what are the particular challenges and opportunities you face?
Edixomed is producing a nitric
‘There is enormous enthusiasm and support for the EAHSN across the region. We have developed a nodal structure so that each of the four centres – Norfolk and Norwich, Eykona has a hand held 3D Colchester, Stevenage as well as imaging device that is changing Cambridge and Peterborough – the way tissue management and have equal share in, and podiatry services are run commitment to, the network and its Polyphotonix has a revolutionary governance. One of my important tasks is to make sure that the treatment for age related network and its constituent nodes macular degeneration and are able to fulfil their potential.’ diabetic retinopthy oxide releasing wound dressing that could significantly improve wound management
Ayseptica has a home based testing kit for those with cystic fibrosis to know when an exacerbation is imminent
uMotif is supporting cognitive function and self-management in Parkinson's patients.
‘We are also establishing networks with Industry and local government partners. In the East we have been able to build on the SBRI programme as well as good networks developed through our innovations hub Health Enterprise East, but the creation of the EAHSN
‘Organisations such as One Nucleus play a critical role in helping establish effective links with the life science industry. We want to hear how we can effectively interact with your members both individually and collectively. We want to learn about the bottlenecks in the development and dissemination of members products. We have ideas about joint events with One Nucleus and other industry partners, and we also hope to develop some useful toolkits and foster information sharing - in particular assisting companies to find the right person in the NHS to connect with, as companies have already said this is a challenge.’ ‘But we need your help to advise us on what is really useful to you and to assist us in creating new solutions.’
BioFocus Signs up for New, Larger Laboratory and HQ Building Churchmanor Estates (joint development partner of Aviva Investors at Chesterford Research Park). ‘Aside from the AstraZeneca deal, this is the largest pre-let in the Cambridge area since 2011 and represents a very significant investment in the region’s economy.’
BioFocus plans to unite the majority of its drug discovery groups within a new a 60,000 square foot (60,000 square metres) building, a move the company says will afford it a unique position amongst CROs for support of integrated projects. The signing of a pre-let agreement with Chesterford Research Park for the new Robinson Building, a state-ofthe-art laboratory facility, was announced in early September. Chris Newton of BioFocus explains: ‘BioFocus has been expanding its research activities at Chesterford
Park, bringing our expertise in different areas such as structural biology, complex cell assays, and medicinal chemistry closer together. Moving the majority of these teams into a single, modern and efficient building is an important step forward for the company and will bring added synergies to both our business model and to our scientists.’
As the Robinson Building already has outline planning permission, construction is expected to start on site almost immediately. The building has been designed as two wings, linked by a two storey atrium and a landscaped courtyard.
‘This is great news for Chesterford Research Park and also for the South Cambridge life sciences cluster,’ said Martin Sylvester of
Geneix Wins TSB Healthcare Challenge for Clinical Excellence Mark Bartlett, co-founder Geneix receiving the award
IC Tomorrow, a division of the Technology Strategy Board, recently awarded Geneix first place for the second challenge in their Digital Healthcare: Clinical Excellence competition. The
challenge was set to look for innovative solutions to leverage clinical and experiential data to improve health outcomes. Geneix presented the concept for their first product InterAct which is an eprescribing system aimed at the secondary care setting which has the power to check a proposed medication against a patient’s drug history for any potential adverse drug reactions. Uniquely, InterAct can also suggest alternative treatments where no known interactions are present and has a strong emphasis on usability. ‘This is an extremely exciting time for us,’ co-founder of Geneix Mark Bartlett commented, ‘The prize will really allow us to move forward
with development, obtain proof of concept and ultimately create a powerful tool to enhance patient safety that doctors also enjoy using.’ In recognition of this achievement Geneix is receiving seed funding, office space at the Google Campus - kindly donated by Healthbox and the possibility to work with two large high profile partner institutions. To keep up to date with Geneix and InterAct visit www.geneix.co.uk
Pathology Diagnostics Accelerates Growth by Building New Research Facility in Cambridge
Pathology Diagnostics (www.pathologydiagnostics.com) is an award-winning GCLP-accredited histopathology CRO, which has recently designed and built a stateof-art facility in Stirling House, Waterbeach in record time, in response to the growing demands of its global client base and grantfunded R&D programmes. The company was founded in 2008 to meet the emerging needs for human tissue-based research to fast-track drug and biomarker development, and boasts clients among the top 10 global Pharma companies and CROs.
CEO Dr Warren stated: ‘Our biggest challenge in setting up the lab was to find a site that would be flexible for our current and future space requirements as our services expand, and remain cost-effective for our clients. It was important to remain based in Cambridge, with its strong scientific reputation.’
diagnostic, digital pathology and hosting capabilities, to transform pathology testing into an objective science.’
The project manager for the lab fitout was Richard Dickinson, One Nucleus’ Director of Specialist Services who has many years’ experience in life science facilities ‘The establishment of the management. ‘One of the main laboratory has allowed us to offer a reasons I joined One Nucleus was complete one-stop service to global to use my facilities background to industry healthcare and academic help SME’s to setup laboratories. clients who are looking for an With my local knowledge and experienced CRO with strong contacts I was able to fit out on scientific credentials which time and within budget.’ specialises in human tissue lab and For further information please diagnostic pathology in early contact: discovery, preclinical exploratory email@example.com and clinical trials research. Our GCLP-accredited HTA-licenced facility includes a histopathology laboratory and state of the art
FluGen-Arecor Partnership Enhances Promise of Universal Flu Vaccine REDEE FLU. FluGen’s universal influenza vaccine candidate, REDEE FLU, is like no other vaccine technology in the world. REDEE FLU tricks the body into believing it is infected but doesn’t bring on the symptoms of the disease. Arecor’s CEO, Thomas Reese Saylor, explains: ‘Arecor has demonstrated its strength in enabling advanced formulations of Arecor received the ‘green light’ live and subunit vaccines through and funding to pursue a research the application of our innovative project applying Arecor’s innovative technology platform, enabling Arestat formulation technology to a market differentiation for major promising flu vaccine, REDEE FLU, vaccine companies in addition to developed by FluGen, Inc., of collaborations with PATH on Madison, WI. The UK’s innovation development of thermostable agency, the Technology Strategy vaccines for the developing world. Board, has awarded Arecor a Proof FluGen's technology represents a of Concept award through its Smart major innovation toward the programme, to engage in research and development in the strategically important area of developing a stable formulation for
development of a universal flu vaccine and Arecor welcomes the opportunity to work with FluGen in applying its technologies to REDEE FLU, enabling a step change in storage and distribution, and ease of administration via intranasal delivery.’ Arecor has a variety of innovative formulation platform tools, collectively referred to as Arestat technology. The breadth of application of these technologies is growing rapidly as Arecor continues to push the boundaries of what is possible to enable liquid-stable biologics.
Eagle Genomics Celebrates Fifth Birthday
The EBI weren’t able to help at that time so Abel used the research from his MBA thesis and teamed up with a colleague, Will Spooner, to give the company what it wanted.
Initially starting out as an interesting idea over a quick pint, Eagle is now based at the Babraham Research Campus, employs over a dozen people and boasts a long list of reputable bluechip clients worldwide. ‘We’re delighted to enter our sixth year of trading. We started out primarily as a service for providing commercial support for opensource bioinformatics tools. Whilst we still do that, the bulk of our business these days is in fact helping people build data analysis pipelines and data integration tools, using the same open-source components as before but delivered as an end-to-end solution that better fits the needs of the market,’ said Richard Holland. ‘At the moment we're closely watching new areas in genomics research such as food and biofuels, where DNA sequencing technology is just beginning to make inroads and the need for bioinformatics expertise like ours is only just beginning.’ And on being located in Cambridge, Richard added ‘Eagle is pleased to be based here in Cambridge, not least for the wealth of talent in the area and the opportunities to be able to mix with academics and businesses across the life sciences and industrial sectors.’ From left: David Flanders, CEO, Richard Holland, CBO, Will Spooner, CTO and Abel Ureta-Vidal, COO
Richard Holland joined as Chief Business Officer a month later and Eagle Genomics was born. As the business grew, David Flanders, with over 25 years’ experience in the life sciences sector internationally, was brought in as Chief Executive in late 2011 to manage the process of bringing in its first round of investment. David’s appointment There’s an old adage that says also solved another long-standing there’s no better time to start a issue: with the company having business than in a recession, but as three founders with equal say in all the economy lurches from doublebusiness-related matters, who was dip to a near triple-dip, the reality really in charge? is it’s a good idea whether you start That same management team is a business during a recession or in still with the company today as the boom times. Eagle celebrates five years of And when money is tight and supplying outsourced bioinformatics companies are looking to either solutions. Put simply, Eagle helps to outsource some of their key analyse the enormous volume of functions or simply looking for “big data” that arises from genomic innovative, cost effective solutions, sequencing on behalf of a range of then some of the best ideas can global companies working in life truly become a long-term sciences, human health, plant, food sustainable business. So when Abel and consumer goods. Just about Ureta-Vidal and Will Spooner sat everything has a sequence but to down in the Eagle pub on Benet understand the data it needs to be Street in Cambridge at the start of mapped, and that takes an the economic downturn in 2008 to incredible amount of processing. discuss setting up their own It’s therefore no coincidence that company, they knew it was a Eagle Genomics is named after The winner. Eagle pub where, on 28 February Abel was working at the European 1953, Francis Crick announced to Bioinformatics Institute (EBI) in the assembled lunchtime drinkers Hinxton while also studying part that he and James Watson had time for his MBA at Judge Business discovered the structure of the DNA School in Cambridge. As he was molecule. looking for a subject for his thesis, Abel hooked on the idea of investigating how commercial business models could be built around open source tools. At the same time, a big pharmaceutical company in the U.S. approached the EBI looking for commercial support to help it make use of the Ensembl platform, a valuable online resource for mapping genome data.
New Corporate Sponsor
Planning Laboratory Relocation in a GxP Regulated Environment Relocations providers need to heed each of these requirements, alongside the IQ/OQ requirement for equipment both pre and postmove, the general acceptance and understanding of GLP/GCP, GDP and GMP in relation to the environment they are working in and the understanding of IATA and ADR Dangerous Goods regulations. In summary, laboratory relocation is a highly regulated area of operation that people can sometimes underestimate in the planning stages. It is apparent that GxP compliance is an issue which will affect many One Nucleus members to some extent and it is an element which should not be underestimated in relation to a relocation project. When moving your laboratory, it is critical to be able to trust that your chosen relocations provider has the skills and knowledge necessary to preserve the required levels of compliance at all times.
significant amount of planning, review and experimental work which will be required to achieve laboratory productivity for each assay, which is likely to take a considerable amount of time both prior to and post-relocation.
Another area of regulatory concern is the relocation of temperature controlled materials under GDP controls and the handling of Manufactured Product covered by The issue is particularly critical for GMP. The long-awaited European laboratories involved in providing Union GDP Guideline was published regulatory standard bioanalysis, in the Official Journal of the when ensuring the continuity of the European Union by the EU performance of assays being used Commission on 7 March 2013 and to generate data. these do contain new regulations for the transportation and storage It is vital that the physical during transit of temperature relocation and re-qualification of controlled materials. laboratory instrumentation is complemented by the reIn particular, the regulations raise establishment of the assays being the need for more stringent used. While the guidelines and scrutiny and use of risk considerations for this are not assessments of transit routes. always defined, the various Additionally, there is increased applicable authorities, including the focus on the calibration and FDA and EMA, both require and validation of in-vehicle temperature expect validation experiments to be monitoring, as well as of the conducted, to ensure continuity. various shippers and containers used for transportation of Sufficient time and resources temperature controlled materials. should be allowed to carry out the
To be sure of a safe and uncomplicated move, ask questions of your relocations provider in order to categorically provide assurance and confidence that they can not only manage the physical handling of laboratory instrumentation, but that they fully understand the critical nature of all other requirements, including the materials needed to transport the items they are handling beyond just loading, transit and unloading at destination. As a corporate sponsor of One Nucleus, Andrew Porter Limited is able to provide extensive free advice to members. The firm is also offering discounts of 15% to Gold members and 10% to Silver members. To discuss any requirements or ideas call 01257 482398 or email firstname.lastname@example.org.
Innovation Leaders Conference 2014: 27-28 February 2014 Innovation happens when brilliant minds come together. At the Innovation Leaders Conference, we seek to promote the translation of cutting edge research into leading products and services - by building bridges between academia, industry and government and linking innovative minds across disciplines. Hosted by the Innovation Forum, a network of multidisciplinary innovative talent based at the University of Cambridge, the Innovation Leaders Conference brings together 300 academics, business leaders, disruptive entrepreneurs and venture capitalists to stimulate communication and catalyse partnering for the next generation of innovative technology. The conference centres on innovation in high-tech industries, with a particular focus on the biotechnology and pharmaceutical
sectors. The two-day meeting in Cambridge will comprise:
Insight keynote lectures from leading R&D executives and eminent academics
Panel discussion on barriers to scientific entrepreneurship
Workshops by industry leaders Poster session and exhibition of companies’ innovative products Confirmed speakers include:
Professor Sir Leszek Borysiewicz: Vice Chancellor, University of Cambridge
Patrick Verheyen: Head, Johnson & Johnson Innovation Centre London
Dr Kevin Johnson: Partner, Index Ventures & previously CEO, PanGenetics
Dr Shai Vyakarnam: Director, Centre for Entrepreneurial Learning, Judge Business School, University of Cambridge
Dr Martino Picardo: CEO, Stevenage Bioscience Catalyst For sponsorship opportunities and early bird registration please visit: www.inno-forum.org
Professor Sir Greg Winter: Master, Trinity College Cambridge & Co-founder of Cambridge Antibody Technologies, Domantis & Bicycle Therapeutics
Looking Forward to Autumn Lorna Cuddon, Managing Director Zyme Communications
Ubiquigent and Urosens.
Zyme Communications Ltd (Zyme), the Cambridge-based public relations and marketing agency specialising in the life science sector, has seen significant growth in the last six months, with new client wins including Abcam, Activiomics, Argenta, Biochrom, BioSilta, Ithaka Life Sciences, Health Enterprise East, Optibrium,
Lorna continued: ‘Autumn is typically our most exciting time of Commenting on the growth of year, with tools and technology Zyme, Lorna Cuddon, Managing clients ramping up communications Director of Zyme Communications, following the holiday season, to said: ‘Each of our new client wins raise awareness and focus on has come from recommendations meeting year-end sales targets. On and word of mouth. We are a small, top of this we are also very senior team with a strong track involved with two major UK events record and we only take on projects before the end of the year where where we are confident that our we manage the press areas and experience and network of contacts arrange media meetings, ELRIG can add real value.’ Drug Discovery 2013, and in Founded in 2010, Zyme provides collaboration with Richard Hayhurst communications support ranging Associates, One Nucleus’ Genesis. from small press release projects, We look forward to a busy Q4 through to fully integrated For more information please visit marketing communications www.zymecommunications.com or programmes involving strategy and contact planning, branding, digital, design email@example.com and development. Zyme’s team of life science communications specialists have both in-house and agency-side experience, and offer the flexibility to support both earlystage companies and large multinationals.
Argenta Oncology Dedicated to Cancer Drug Discovery area knowledge with the latest technologies and state of the art capabilities. The Argenta Oncology team has run over 30 integrated drug discovery projects for both haematological and solid tumour indications, which have covered all small molecule target classes including kinases and epigenetic modifiers. Their track record is unprecedented, with six Oncology is an area in which oncology clinical development Argenta has built extensive incandidates delivered to clients and house expertise over the last nine more than 65 oncology related years, and now has a large group of patents and publications. experienced oncology scientists spanning all aspects of cancer drug John Montana, Managing Director of discovery. Argenta has consolidated Argenta, commented: ‘Argenta this key therapeutic area know-how Oncology represents a great into Argenta Oncology, providing an opportunity for potential partners enhanced drug discovery offering as it provides them with truly focused expertise in cancer that combines excellent disease
therapeutics, and they can be confident that they will obtain the best possible outcomes for their oncology projects.’ In addition to the fully integrated discovery projects, Argenta Oncology can also carry out bespoke oncology projects such as dedicated assay development, MoA/ biomarker studies, and oncology focused medicinal chemistry. If you would like to know more please email firstname.lastname@example.org
Early Diagnosis Consortium – Abcodia Collaborates with Cancer Research UK and CRT Dr Julie Barnes, CEO, Abcodia
potential serum biomarkers, biomarker panels or statistical algorithms for a range of cancers that can be used for screening of individuals at high risk of cancer or the population in general. Cancers with a high degree of unmet clinical need, for example lung cancer, are likely to be selected. Once these validated biomarkers are identified, the aim is to further test them in prospective studies and make them available for use in the UK and around the world. Abcodia, the biomarker validation company with a focus on cancer screening, has joined forces with Cancer Research UK and its commercial arm, Cancer Research Technology (CRT) to develop new blood tests to detect a range of very early stage cancers. This partnership, known as the Early Diagnosis Consortium, aims to discover, verify and validate
(UKCTOCS) run at UCL and contains more than five million serum samples. Dr Julie Barnes, Abcodia’s CEO, said: ‘We are delighted to be able to work with Cancer Research UK and CRT in this new global venture. The early diagnosis of cancer has never been more important and with the collective expertise that this alliance can bring, we aim to make a real difference in the field of early cancer detection and screening.’
The partnership combines Cancer For further information about the Research UK’s extensive clinical Early Diagnosis Consortium, please oncology and scientific network see: www.abcodia.com/ with Abcodia’s expertise in the longitudinal profiling of biomarkers, as well as its exclusive access to one of the world’s largest prospective collections of serum samples available for biomarker research. This collection is derived from the UK Collaborative trial for Ovarian Cancer Screening
PolyTherics Merges with Antitope and Raises up to £13.5M technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world’s top companies. Dr Burt will be CEO of the enlarged group and Dr Matthew Baker will continue as Chief Scientific Officer for Antitope, which will retain its base, management and operational structure at the Babraham Research Campus, near Cambridge.
PolyTherics has merged with Cambridge-based Antitope in a strategic move to expand its portfolio of technologies and services that enable the development of better biopharmaceuticals. PolyTherics issued new shares up to a value of £13.5 million to fund the merger and to provide working capital for the enlarged group. Imperial Innovations led the investment and brought in new investor Invesco Perpetual, with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.
said: ‘The combination of PolyTherics and Antitope is a significant strategic step, immediately broadening our business and accelerating our growth.’ Antitope, which will become a wholly owned subsidiary of the PolyTherics group, brings expertise in immunogenicity screening and antibody engineering to complement PolyTherics’ nextgeneration antibody drug conjugate and pharmacokinetic optimisation
Dr Baker said: ‘The combination of Antitope with PolyTherics provides an excellent opportunity for us to expand and grow our offering to our existing partners. The combined company will have critical mass in terms of technologies, skills and resources and will enable us to leverage the full potential of our antibody engineering and deimmunisation platforms. We are delighted to become part of the PolyTherics group and believe this move will enable us to support growing demand for our technologies from the global biopharma industry.’
Dr John Burt, CEO of PolyTherics,
Target Harvest Festival Michael Dalrymple, Director of Business Development, MRC Technology
Charities across the UK do a great job in attracting public monies to fund research into their disease(s) of choice. However, while many charities have their own laboratories and funded Principal Investigators, there will always be gaps in research capabilities. One of these gaps is early stage drug discovery – namely small molecule screening, medicinal chemistry and antibody engineering. MRC Technology has many years’ experience in
advancing small molecules and antibodies to market, including supporting academic research from the Medical Research Council. Two approved products originated in MRC Technology labs: Tysabri and Actemra For several years now, MRC Technology has been working with university researchers, giving access to its facilities through the Call for Targets programme (www.callfortargets.org) where (Continued on page 15)
Member News promising targets can be developed. Medical research charities are now also being supported by MRC Technology scientists, adding value to their research spend and helping to progress promising targets through to the clinic. Joint calls to academic researchers seek to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project. MRC Technology uses its expertise to help select likely targets for further development, for which the charities then provide funding. To date MRC Technology has carried out joint calls with the MS Society, Parkinson’s UK and most recently Arthritis Research UK. The charity
Autumn 2013 can then choose either MRC Technology, on a shared risk basis, or another organisation as its commercial development partner.
dormant or parked targets from biotech companies. These undeveloped targets may have been put on hold or abandoned for commercial reasons. As a charity Where MRC Technology is the itself, MRC Technology’s objectives chosen development partner, are to deliver advances in projects progress to MRC healthcare and generate Technology’s Centre for Therapeutic investment to fund further Discovery (CTD) based in Mill Hill, research. It may be that companies London, where small molecules or have deemed the market to be too therapeutic antibodies are niche, or have other priorities – generated against the targets. If a MRC Technology will carry out its programme is successfully own evaluation and take on such developed to partnering stage, MRC projects if it feels there is life in a Technology can lead on target yet. commercialisation, with revenue share for both parties. For further information on how MRCT can help develop or take on However, target work is not limited drug targets please contact to academics or charities. MRC email@example.com Technology is looking to acquire
F-star Awarded Biomedical Catalyst Feasibility Grant to Create Novel Anti-Cancer Therapies John Haurum, CEO, F-star
F-star, a biopharmaceutical company focused on developing novel bispecific antibody products, recently announced the company has received a Biomedical Catalyst Feasibility grant from the Technology Strategy Board, to support the evaluation of a targetspecific conjugate for cancer therapy.
directly to the target cancer cells where the drug can then be released. This targeting effort allows for a potential reduction in side effects and a wider therapeutic window. F-star has already used its proprietary technology platform to generate an Fc fragment of an antibody (an “Fcab” or an “Fc with antigen binding”) that binds potently to a unique domain within a breast cancer target. Overexpression of the target plays an important role in the pathogenesis and progression of certain aggressive types of breast cancer, and in recent years it has evolved to become an important biomarker and target of therapy for the disease.
F-star will utilise technology created by Heidelberg Pharma GmbH to conjugate a toxin to the target-specific Fcab. Heidelberg Pharma has developed a technology for antibody-drug Antibody-drug conjugates consist of conjugates based on the an antibody (or antibody fragment) conjugation of novel toxins to linked to a payload drug, often a antibodies. In this collaboration cytotoxin. The antibody component with F-star, Heidelberg Pharma will enables the therapeutic to bind take a new approach and apply its
technology to an Fc fragment of an antibody. F-star will then evaluate the resulting antibody-drug conjugate alongside current standard of care treatments. The unique properties of Fcabs suggest that they will be particularly well suited to an antibody-drug conjugate approach. ‘This grant will help us realise the exciting potential for the development of antibody-drug conjugates derived from our versatile Modular Antibody Technology platform,’ said John Haurum, Chief Executive Officer of F-star. ‘The funds from this award will enable F-star to continue our efforts to create superior, novel anti-cancer therapies that have the potential to make a significant difference in the treatment of disease.’
Stem Cell Start-up in Global Rollout Cerebral Cortical Neurons from Axol
billion global neurobiology research market – is regarded as having a significant ethical edge as its products eliminate the need for testing human disease pathologies in animal models. Axol is applying cutting-edge stem cell technologies to generate high quality human neural stem cells and neurons. Cerebral cortical neurons are implicated in numerous neurological diseases including Alzheimer’s, autism, epilepsy, traumatic brain injury and stroke. Despite growing support for research in these areas, high quality human in vitro cell models for cortical neurophysiology have been unavailable until now. Axol has led the launch of its technology Less than a month after shipping its with a focus on providing both first order, the pioneering UK healthy and Alzheimer’s disease business has recruited a five-star relevant human neurons derived list of international distributors from iPS cells. covering major markets around the Axol Marketing Director, Naomi world. Wessel-Carpenter, said: ‘Working Axol’s proprietary brain stem cells with such renowned distribution are produced from reprogrammed partners provides a great human blood cells, known as iPS opportunity to introduce the unique cells, and the new distribution advantages of our iPS cells and network will manage sales and differentiation technology to the support in the US, Japan, global research markets.’ Scandinavia and several territories ‘We are pleased to partner with in mainland Europe including Germany, Italy and Switzerland. such experienced teams, characterised by a history of The move marks a strong exceptional customer and statement of intent from the young technical support.’ business which is backed by Abcam CEO Jonathan Milner, now also Arguably the most influential chair of Axol. distributor in the network is United States Biological – Axol – primed to address a $15 headquartered in Boston with a Cambridge stem cell technology startup Axol Bioscience has made a lightning fast opening to its global commercialisation strategy.
North America-wide spread and a global reach through 70+ distribution partners worldwide. Its customers include most of the leading pharmaceutical and biotechnology companies located in the US and abroad as well as global academic researchers. President & CEO Warren Shore said: ‘The ready-made, wellcharacterised stem and functional cells derived from iPS cells provided by Axol nicely complement our portfolio of distributed and internally developed products for life science research markets.’ ‘Working closely with the Axol team, we will be able to provide our customers with robust, time saving solutions for their discovery and validation projects.’ Other leading players in the Axol distribution network are Cosmo Bio in Japan, Caltag Medsystems in the UK, Labospace (Italy and UK), LuBio (Switzerland), Biozol (Germany and Austria) and Bio-Mediator (Finland, Denmark, Sweden and Norway).
Article first appeared in Business Weekly, 22 August 2013
Cerebral Cortical Neurons from Axol
STRATUM - Strategic Tissue Repository Alliances Through Unified Methods sample catalogue with a minimum dataset, consent templates with guidelines, recommendations for funding and constructing a national coordinated biobank network.
The project primarily set out in November 2011 to resolve the problem of insufficient, high quality HBS available for research. Since then, it has engaged with key public and private stakeholders, including the Experimental Medicine Funders Group, to deliver a vision for Human Tissue Resources. This has resulted in STRATUM delivering a toolkit and expert reports comprising policies, technical standards in sample life cycle management, requirements for a
1. A Distributed Research Infrastructure is ‘a singular Research Infrastructure, having a In order to enable adoption and unique name and legal status, implementation of STRATUM, an director or board of directors, exploitation plan has been management structure, strategy developed which specifies the and development plan, access point approach and work needed to for users, annual report and fiscal implement the STRATUM address, although its research deliverables as a ‘pilot’, with the facilities have multiple sites’. initial focus being in the respiratory http://ec.europa.eu/research/ community, but with applicability to infrastructures/index_en.cfm? all disease area communities and pg=esfri-workingas a public-private partnership. The groups§ion=distributedultimate goal is for a co-ordinated facilities network, potentially as a Distributed Research Infrastructure For more information visit http:// (DRI)1 in biobanking, to enable stratumbiobanking.org/ exploratory research in areas of pre -competitive collaboration, and to support the delivery of stratified medicines and their adoption. The benefits from dissemination and adoption of the STRATUM deliverables will be to drive opportunities in stratified medicines through equitable availability of high quality samples that will increase the probability of success
Stevenage Bioscience Catalyst Forging Big Connections Anyone who calls Stevenage Bioscience Catalyst (SBC) the ‘GSK Incubator’ has undoubtedly not heard about the corporates that have recently announced tenancy at the 10,000 m2 site. SBC is the UK’s first open innovation bioscience campus, co-located on the GSK R&D site in Stevenage and supported by Government, industry, and the charitable sector. Its remit is to assist early-stage bioscience companies through access to commercial expertise, routes to funding, and most importantly, by fostering a culture of open innovation.
In this vein, one of the latest pharma to establish a presence at SBC the London-based J&J Innovation Centre, which aims to identify exciting new assets, technologies and companies for partnership through regular interaction with the 26 tenants and wider network that comprise the SBC community. Dr Martino Picardo, CEO of SBC, said 'We are delighted that Johnson & Johnson Innovation in the UK has decided to establish a partnering office at SBC, in a natural extension of our unique pharma incubation
model. Innovation is a collaborative and serendipitous process and SBC is working with partners like this to create an environment where it can flourish. With its broad expertise, J&J is a great partner as we look to catalyse innovation across healthcare, from drug discovery to convergent medical technologies.' Not restricted to the big pharma, (Continued on page 17)
Example of use of Tissue for Disease Stratification: Patient to Target Cell
STRATUM is a public-private funded research project in biobanking, for human biological samples (HBS), under the Technology Strategy Board (TSB) programme for ‘business models and value systems’ in Stratified Medicine. It is sponsored by AstraZeneca (AZ) and partnered by GlaxoSmithKline (GSK), Lab21 and Leicester, Manchester and Nottingham universities.
in the R&D value chain.
Autumn 2013 universities are also part of the mix Cambridge continues its collaboration with GSK to progress its drug candidates, and a London university is under discussion with SBC about bringing several projects into the fold. Other universities engaging with tenants include Bristol and Manchester. However impressive the actual facility is, far more inspiring is SBC’s growing connections between big pharma and healthcare companies, academia, charities and SMEs to advance biomedical discovery - a true feat of open innovation.
Horizon Discovery Expands its Gene Editing Platform by Licensing both ZFN and CRISPR Technologies Horizon Discovery announced in September that it has added both Zinc Finger Nuclease (ZFN) and CRISPR technologies to its GENESIS gene editing platform, to sit alongside its proprietary rAAV technology. The licensing and IP deals place Horizon in the unique position of having the commercial freedom to apply all three technologies in the company’s custom cell line generation service and to further expand its menu of over 500 isogenic cell line pairs. Horizon says it now offers the broadest set of gene editing tools available from any translational genomics company.
Until now, Horizon has been organised around a single gene editing technology, rAAV, but it has become increasingly apparent that researchers are more concerned with the solution than the approach. In response, they made the strategic decision to become technology-agnostic, bringing in additional technologies that better allow them to meet customer needs.
ZFNs with our proprietary rAAV technology, Horizon is working to develop novel approaches that achieve levels of gene editing efficiency not previously seen when using any single approach alone.’
Dr Darrin Disley, CEO of Horizon, said: ‘Horizon is a full service translational genomics company, encompassing identification of the genetic drivers of disease, the creation of human disease models Horizon believes that being the only and their application in the translational genomics company development of targeted molecular able to drive research programs therapeutics. Access to ZFN, through the application of both CRISPR and rAAV gene editing nuclease and rAAV-based gene enables us to give our customers editing, coupled with their in-house the best-in-class solution for their gene editing expertise and research needs. Horizon’s scientists collaborative approach to working now have the freedom to choose with customers, places them in a the best technology, or combination unique position to deliver value. of technologies, to most effectively achieve the specific goals for each Eric Rhodes, CTO of Horizon, said: project.’ ‘Nuclease based approaches are particularly adept at achieving rapid and efficient knock-out of two or more alleles, making them a perfect complement to Horizon’s proprietary rAAV-based precision gene-editing platform. Moreover, by combining both CRISPR and
CrownBio Strengthens Oncology Expertise with Acquisition of PRECOS Jean-Pierre Wery, President of CrownBio
North Carolina (USA), Beijing (China) and Taicang (near Shanghai, China.) PRECOS has a 15 year pedigree of delivering reproducible, patient-relevant in vivo and in vitro oncology models as a business unit of the University of Nottingham. In 2010 PRECOS became fully independent to provide a solely commercial service to its clients.
Neil Rotherham, chairman of PRECOS
Neil Rotherham, Chairman of PRECOS, said: ‘The acquisition of PRECOS by Crown Bioscience will enable PRECOS to continue expanding its business as part of a larger organisation, giving Crown Bioscience’s clients access to PRECOS’s unique and growing panel of Patient-Derived Xenograft (PDX), orthotopic and metastatic modelling and imaging services. Our innovative models and expertise provide a perfect complement to Crown Bioscience’s robust panel of models and services, and our geographical location provides a European hub for Crown Bioscience’s rapidly expanding client base in Europe. The security of being part of a larger, global and rapidly growing organisation like Crown Bioscience will enable us to continue to invest in providing leading-edge model development services to the wider oncology drug discovery community.’
CrownBio leads the field in providing unique translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in two dedicated therapeutic areas: Oncology and Metabolic Disease. Headquartered in Santa Clara, California, the company also has research facilities in Kannapolis,
For more information please visit www.precos.co.uk
CrownBio’s Beijing site
Crown Bioscience (CrownBio) recently announced that it has acquired the shares of One Nucleus member PRECOS, the Nottinghambased contract research organisation focused on providing clinically relevant oncology models for drug discovery. As a result of the acquisition CrownBio becomes the world’s only contract research organisation that offers such a comprehensive range of services. It will become the largest supplier of Jean-Pierre Wery, President of CrownBio, commented: ‘The oncology services with a global footprint, spanning three major continents in North America, Europe and Asia Pacific.
acquisition represents the next step in expanding the range of specialized services we offer pharmaceutical and biopharmaceutical customers worldwide. PRECOS has unique clinically relevant models, which reflect the patient situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumours and metastasis.’ Jean-Pierre continues, ‘We are delighted to have completed the acquisition of PRECOS, which offers Crown Bioscience an immediate footprint in Europe with a significantly sized organisation to support engagement with European and global clients, as well as develop cutting-edge models and services for Crown Bioscience’s existing client base.’
Exploring the India Opportunity The Indian healthcare industry, comprising hospitals, medical infrastructure, medical devices, clinical trials, outsourcing, telemedicine, health insurance and medical equipment, was valued at £51 billion in 2012, and is expected Entering and expanding in an to reach £103 billion by 2017. A overseas market is not easy, growth of ~15% year-on-year is whether the company is large or anticipated due to factors such as small. It is a risk that often must be rapid infrastructure development, taken however in order to grow a demand for higher quality business. Ludo Chapman, Managing healthcare, raised awareness and Director of Grant Instruments, a expectation from end users, and Cambridge-based provider of launch of innovative insurance, scientific equipment and data reimbursement and financing acquisition and analysis solutions, policies. took the plunge when he decided to As India’s Five-Year Plan take the company to India. emphasises universal healthcare, Grant Instruments operates in over India is increasingly proving itself to 140 countries worldwide, and has be a natural healthcare partner for always sold to India on an ad-hoc the UK. Key opportunities for British basis, filling specific orders as and companies lie within healthcare when they came in. However, four technology, medical devices, years ago the company embarked affordable diagnostics, publicon a growth strategy to focus on private partnering to deliver large emerging economies, innovative care, emergency care, specifically India and China, education and professional deciding to set up its own development. distribution network in these Various routes are available to UK regions. After a three week visit to businesses looking to enter the India Grant Instruments had set up India market with options including: an office to represent them on the ground, and hired a local Direct to clinicians and hospital representative. Grant Instruments procurement now has its own distribution Partnership with major network and is looking to find healthcare groups additional agile partners to help grow the business.
channels When choosing a market, it is advisable to look to the emerging 2nd and 3rd tier cities thus avoiding the expensive, over-crowded mega cities. The next round of economic growth is predicted for emerging cities such as Pune, Nagpur, Kochi, which offer good infrastructure and better value. Businesses should also look for sector-specific clusters such as Bangalore for IT, biotech and aerospace; Pune for manufacturing, skills and education; Hyderabad for IT and aerospace. In support of British companies entering India, and especially SMEs, the UK India Business Council has opened Business Centres in Gurgaon and New Delhi. Through services such as India Readiness Programme and Launchpad, and hot -desk and office space facilities, companies can make their India entry a low risk one. Richard Heald, Chief Executive, UK India Business Council, said ‘I urge British companies not to miss the opportunity that India offers. You should examine the fast growing sectors, understand the brand and price conscious consumer market, and study the cities and states that hold the best prospects for your entry and growth.’
Rt. Hon. Patricia Hewitt, Chair, UKIBC and Richard Heald, Chief Executive, UKIBC at a pooja for the new UK India Business Centre in Gurgaon
India is a large, fast-growing economy, with this growth largely driven by domestic demand, fuelled by a rapidly growing middle class. It has 572 million people under the age of 24, giving it the biggest youth population in the world. According to the Organisation for Economic Co-operation and Development (OECD), India's middle class will expand from 510% of the population today (1.2 billion) to 90% by 2039. India therefore presents significant opportunities for UK businesses, goods and services, including healthcare products and services.
Supporting Innovation Regionally and Nationally development process.
The NHS Innovation Team at HEE
As a whole, HEE is developing its relationship with the newly formed Eastern Academic Health Science Network (EAHSN), providing innovation and industry engagement support to meet the strategic needs of the Network.
A leading NHS Innovation Hub for the last eight years, Health Enterprise East Limited (HEE) is the NHS Innovation Hub for the East Midlands and East of England, assisting with the development and uptake of innovative MedTech products and services that improve the quality of healthcare delivery and meet the needs of the NHS. With membership up by 25% in the last year these are busy times for HEE, based at Cambourne Business Park in the heart of Cambridgeshire. The NHS Innovation Team has had a highly successful year identifying and
developing a number of new projects from within the NHS which have potential to significantly improve both commercial and patient outcomes. The possibilities for are such that HEE is developing a new innovation model to secure backing for these ideas and ensure the value is fully realised for the benefit of the NHS. On the other side of the organisation, HEEâ€™s Medtech Services team continue to offer professional support and advice to medical technology businesses, assisting them in gaining access to clinical insight during the product
Part of the role with the EASHN is to provide the project management and monitoring expertise to deliver the award winning Small Business Research Initiative (SBRI) programme. This national precommercial procurement programme invites companies to apply for funding to solve identified unmet needs within the health service. A new ÂŁ5m programme has recently with the largest ever number of clinical themes. Further information on the services Health Enterprise East can provide and details of the latest SBRI Healthcare competitions can be found at www.hee.co.uk and www.sbrihealthcare.co.uk respectively.
One Nucleus News
ON Helix – The Perfect Recipe focusing further on the collaborative approach to supporting translational research, including presentations from Cancer Research Technology and Kymab Access as well as a very lively set of presentations, and a debate on Science Network) took to the
meeting the translational research
challenge with gusto as the
challenges, led by Allan
Sir William Castell, Chair of the Wellcome Trust
Keynote Speakers. They showcased Marchington of Apposite Capital and how the UK has fantastic
showcasing the likes of local
opportunity – with it’s academic
companies Discuva and
excellence, science hubs and
MedImmune. Mark Treherne, local
research facilities. Sir William urged boy and CEO of the UK Life Science delegates to ‘be bold’, and to push
Investment Organisation, chaired a
the boundaries to help make the UK great session showcasing the ‘the knowledge shop of the world’.
support available in the translational research space,
The line up of speakers was then
including presentations from NOCRI
truly stellar with the recently
and the Technology Strategy Board
knighted Sir Mike Stratton
– importantly with an exclusive
showcasing the application of
announcement from Helen Kuhlman
genomics for human health on the
of the TSB that the next BioMedical
panel session chaired by Sir
Catalyst would launch that week.
ON Helix, One Nucleus’ brand new
William, and presenters showing
conference, took place on 9 July in
how to turn early stage inventions
The final presentation of the day
splendid style at the Genome
and ideas into innovative health
offered something a little out of the
ordinary. Inspirational speaker Andy McMenemy held the audience
The day saw an impressive range of One of the key points that ran
captive with tales of the Marathon
presentations around the key
throughout the day was the
des Sables and his 66 ultra-
theme of translational research.
importance of great partnerships
marathons in 66 days around the
How to overcome innovation gaps
and collaborations. The afternoon
UK, encouraging delegates to face
is a key issue for many life science
saw panel sessions and workshops
the challenges of business head on,
researchers, and although these topics have been covered at other conferences in the past, ON Helix is the first to bring the life science industry and academia together to discuss how to bridge this gap between basic research and marketable product. The question being addressed was ‘Why do your translational research in the UK’ and the exceptional double act of Sirs – Sir William Castell, Chair of the Wellcome Trust and Sir Mike Rawlins, Chair of the Eastern AHSN (Academic Health (Continued on page 22)
One Nucleus News
Her work has appeared in Sir Mike Rawlins, Chair of the Eastern AHSN (Academic Health Science Network) and Jane Southgate, artist
neurology magazine ACNR and is due to be on the cover of Cortex later this year. She leads numerous art workshops with a wide variety of groups ranging from children to adults with learning difficulties, OAP’s to business people. The One Nucleus team has been thrilled with the success of our new event in its first year. The fantastic Advisory Board and quality of presentations, partnering meetings and the programme throughout the day contributed to the perfect recipe for a relevant event for the sector. We are now very much to focus on your end goal and to
Helix was a great day, very well
looking forward to capitalising on
know that you can achieve your
attended and with a fantastic line-
the excitement of ON Helix and
dream, before joining them on the
up of speakers. It shows the
bringing it back in 2014 - providing
terrace for the drinks reception to
importance of addressing
a vital forum for addressing key
close the conference.
translational research topics
issues in translational research and
amongst the life sciences
reviewing what has happened since
The 300 delegates certainly
community. It is a great showcase
ON Helix 2013.
enjoyed the day, giving excellent
for the strength of biomedical
feedback on the content of the
innovation in the southeast of
ON Helix 2014: 2 July 2014 at
conference and quality of the
networking. Claire Brown of AstraZeneca said ‘An excellent first
More information at: Jane Southgate
It was a first for One Nucleus to
For more information contact
conference’, John Haurum of F-Star commented ‘Great event with an
impressive line-up and attendance’, combine a conference with an Linda Allan of the University of
exhibition and we were very proud
Cambridge said ‘Excellent and has
to have Jane Southgate exhibit her
already proved very useful’, and
work at ON Helix. In her exhibition
Ralph Minter of MedImmune
Jane celebrates the work of those
remarked ‘Great opportunity to be
pioneering scientists who played
inspired by some of the pioneers in
their part in the discovery of DNA,
the field and to meet potential
and extolls the beguiling nature of
the microscopic structure itself.
In commenting on the Conference
Jane has exhibited widely and
Sir Mike Rawlins said ‘ON Helix is
undertaken many commissions for
THE translational event in the UK
both businesses and individuals, Sir
where all participants can expect to Mike Rawlins bought a piece as a network at the highest level with
gift for a friend based in the USA.
each other and learn an incredible
She has had residencies with the
amount all in the one day. It’s
British Trust for Ornithology,
Suffolk Wildlife Trust, Manor House Museum, and Stowhealth.
Sir William also commented ‘ON
One Nucleus News
Sector Gets To Work on Manifesto for Life Sciences issues. Events are underway to
‘BioPartner welcomes the chance to
provide an early platform to get
unite with the sector to promote a
unified voice to policymakers on the
BioCap – was held on 18 September (run by Bionow)
BIA UK Bioscience Forum – was held on 10 October (run by BIA)
BioEurope breakfast – to be held on 5 November (run by BioPartner)
Genesis – to be held on 12 December (run by One Nucleus) Work to gather sector views for the development of a Life Science Manifesto for the 2015-20
Steve Bates, BIA Chief Executive Officer, said:
key issues that matter to companies and ensure the UK is an attractive location for life science activities and inward investment. We will use all opportunities to raise the profile of this initiative overseas starting at BioEurope on the 5th November.’ Harriet Fear, One Nucleus Chief Executive, said: ‘One Nucleus works hard to ensure our members’ voices are heard through the BIA at the national
Parliament is well underway as part ‘Through the Life Science Manifesto of the collaboration bringing project the sector will have a
level and the Life Science Manifesto
together the BioIndustry
chance to identify what we feel are
collaborative approach across the
Association (BIA), Bionow,
the core needs and asks for the
sector to deliver greater impact. I
BioPartner UK and One Nucleus.
next Parliament so that the BIA can look forward to discussing the issues at our Genesis event later in represent these views to
The Life Science manifesto 2015-20 project seeks views from companies and organisations from across the UK to develop the key sector asks and needs for the next Parliament. Experience has shown time and again – most recently with the successful campaign for the continuation of the Biomedical
policymakers in Whitehall, Westminster and Europe. Working in partnership with Bionow, BioPartner and One Nucleus will ensure the sector voice is effectively heard in a coherent way by parliamentarians and others.’ Geoff Davison, Bionow Chief Executive Officer, said:
Catalyst scheme – that a unified
‘Bionow members have the
and coherent sector voice is most
opportunity to make their views
powerful and effective in achieving
known and influence policy
results and positive change.
decisions at a UK level and at our
The Life Science Manifesto project will enable the life science sector to take stock, assess the current environment and identify the key policy opportunities and challenges in the years ahead to reflect to policymakers. It is inclusive and UK
BioCap event have the first chance to identify and discuss the key challenges to be overcome. I am excited about the opportunity to promote the needs of companies based in the North of England to policymakers.’
-wide with numerous opportunities
Lin Bateson, BioPartner Executive
for engagement including ‘voting’
with ballot papers on key policy
work will ensure a coordinated and
One Nucleus News
One Nucleus Leadership Series Update
collaborations in this area, and the challenges of taking such technologies into clinical practice. Professor Sikora highlighted the expected tripling of the cancer treatment market by 2023 from US$65Bn in 2012, with novel technologies set to play a significant role. Taking an optimistic viewpoint, he pointed out that the increasing adoption of cancer diagnostics, biomarkers and surrogate endpoints into both R&D and treatment strategies could see 96% of cancers being controllable by 2063.
The One Nucleus Leadership Series of events is designed to provide high calibre forums with clear focus for a specific therapeutic area, technology approach or business strategy. The strong focus enables research leaders and company executives actively engaged in each theme to be assured that every meeting will provide informed debate and a valuable forum for knowledge sharing, with the end result that we collectively deliver greater success in the sector. The Personalised Medicine event 23 May 2013 attracted a full house. Opening the day and speaking in the plenary session were Professor Karol Sikora (TranScrip Partners and CancerPartnersUK), John Mills (AstraZeneca) and Elaine Warburton (QuantuMDX). The session highlighted the significance and potential impact of introducing stratified medicine approaches in cancer, what Pharma is looking for in its partnerships and
John Mills expertly articulated the drivers within AstraZeneca’s partnering strategies in the field, explaining the importance of timing of technology adoption in the product development cycle, key characteristics of a successful partnership, and the key criteria AstraZeneca is looking for in a potential collaboration.
Teale, GfK Bridgehead) environments, giving delegates food for thought when considering their own product development and commercialisation strategies. Mark Ecclestone presenting the VolitionRx approach to revolutionising cancer diagnostics was another highlight. The closing session of the seminar saw Darrin Disley of Horizon Discovery describe the company’s business model, and how they have built shareholder value from a range of personalised medicine technologies. Dr Disley was followed by Alastair Gaw detailing how the Technology Strategy Board is enabling R&D in stratified medicine in the UK. Alex Clarkson of Diagnostic Capital closed the day, setting out where he sees the commercial potential in personalised medicine and why investors should be taking note.
The closing session of the Personalised Medicine event, along Elaine Warburton used the with networking meetings and development and commercialisation round table discussions over the of QuantuMDX’s Q-PO and Q-SEQ summer, leads nicely into the products as case studies to Investment Strategies in Life exemplify how global humanitarian Sciences Leadership Seminar be need, technology and economics held on 25 September 2013. are creating the conditions for change. She looked at how doctors Has there ever been a time when changed their prescribing habits cash wasn’t the main worry for life and patients get immediate science sector executives? Raising diagnostics results, leading to the investment is not an easy task in right patient receiving the right any climate, and the recent past drug at the right time; personalised has certainly been extremely medicine in its truest form. economically challenging across all sectors. Encouragingly there are Subsequent speakers took their positive signs of late, with a rush of lead from the plenary session, IPOs for life science companies in describing the changing regulatory the US showing no sign of abating, (Catriona Cutting, GFA), intellectual property (Tanya Heare, Venner (Continued on page 26) Shipley) and market access (Chris
One Nucleus News
players active in cross-border activity The changing investment picture across the industry Larger corporations and NGOs are playing an ever increasing role in the incubation of innovative technologies, whether directly through project funding or through more integrated R&D collaborations with early stage innovators. The role these stakeholders are already playing, and could play in future, in early stage company creation was discussed by a panel chaired by Rowan Gardner that included Richard Seabrook (Wellcome interest growing in the London the sector through schemes such Trust), Jeanne Bolger (Johnson & capital markets for the more as the Biomedical Catalyst, Johnson Development Corporation), technology-based healthcare plays, Patent Box and R&D Tax Credits, Elaine Sullivan (Eli Lilly R&D and Mirror Funds), and finally Tony and a number of new entrants and but the question remains as to Government support schemes to whether the life science sector is Sedgwick provided a company fuel the emerging life science making the appropriate business founder viewpoint. vehicles. Getting the investment case for long term growth and Next on the agenda was a panel strategy correct in order to build where the sector should be debate chaired by Tony Sedgwick and realise commercial value longer asking Government to invest which looked at the growth capital term is still a challenging process going forward. arena. The panellists included Geoff however. The seminar commenced with an in Nash (FinnCap), Claire Dorrian (London Stock Exchange) and We were delighted to assemble a -depth look at the opportunities first class speaker faculty for the offered by doing business in India. David Phillips (SROne), who September event, with the help of Led by Accelerator India, the described how they are seeing our Advisory Board of Rowan presenters discussed how key greater interest from both sector specialists and generalist funds in Gardner (BioLauncher), David stakeholders interact in the Phillips (SROne) and serial emerging eco-system, with specific the City in terms of life sciences. entrepreneurs and business angels reference to: They qualified this by pointing out that interest is primarily in Andy Richards and Tony Sedgwick. Government and private sectorWe elected to look at the question technology-led companies rather funded research activities, from a different perspective to the than drug development, in contrast including incubators standard public sector ‘support to to the US markets. Some excellent examples of recent success were early stage finance to exit’ strategy Emerging SMEs in the main programme formats, on the basis described, including Clinigen, national clusters that: (Continued on page 26) National and multi-national If we are to see innovative products developed and generate economic development by retaining the human capital available, then we need to look at how we start more life science companies
Growth capital is key, and we are seeing a number of new style entrants such as Family Offices and crowd-funding platforms join the already established corporate VCs and capital markets
The British Government has made great strides in supporting
One Nucleus News stage space and in initiatives such as One Start with the Oxbridge Biotech Roundtable. What has perhaps been less obvious is the benefit of having a Corporate VC as an investor when it comes to growing the company. Progenitor Labs talked us through the benefits they have seen from having SROne as an investor, not only through access to funding but also increased access to facilities and SROne’s ability to open doors to the appropriate collaborators and expertise within GSK for future deals, all meaning the investee has the best possible chance of e-Therapeutics, and Cambridge succeeding. The success rate of Cognition. Sareum were also corporate VC backed life science highlighted as an example of how companies versus those without is secondary financings are working in robustly predictable, whether or not the sector, but this didn’t detract the investee company is from David Phillips articulation of subsequently acquired by the the need for private capital parent corporate. providers such as VCs to see an The seminar concluded with Andy exit in a meaningful timeframe, and Richards leading a panel consisting the benefits of being able to take a of Ed Hodgkin (Syncona Fund), Phil longer timeframe into account as a Boyd (ex-Syntaxin CFO) and Tom Corporate VC. Saylor (Arecor), reflecting on the Drivers behind Family Offices and investment strategies and their timescales were also challenges debated earlier in the discussed, and found to be varied day. The current Government and complex as one may expect. It interventions were put into context, is really a case of leveraging your and the question of whether future (or your adviser’s) network of interventions needed to be different contacts in that space to secure the was assessed. Further debate took right capital. A commitment to place over a closing network nurturing the desired pipeline of reception and a subsequent opportunities was shown by SROne, Cambridge Enterprise Venture who have been active in the early Partners Dinner, followed the next
day by the annual Babraham Investment Forum where company strategies were in the spotlight. In the next of our Leadership Series events, on 14 November at the Queen Mary Bioincubator we will be looking at current approaches in neurodegeneration treatment development. This is a follow from the very successful Alzheimer’s diseases session from February, and very timely given the Government’s continuing focus on dementias. One Nucleus’ annual Genesis Conference held in December will see the themes of the Leadership Series showcased, with sessions on ‘Biomarkers in oncology’, ‘Imaging in CNS’, ‘Antibody drug development’ and ‘Using Big Data in R&D’, alongside a variety of other sessions including therapeutic area deal case study debates. Turning to 2014, our next Cambridge-based Leadership Series event will combine two previous themes as we return to the Babraham Campus on 11 February 2014 for Antibody-based Therapeutics in Oncology. This will be followed by Personalised Medicine in May 2014. For more information contact firstname.lastname@example.org
One Nucleus News
Bon Voyage Philip! At the end of August, our Business Development & Training Manager, Philip Kendall, left One Nucleus after nearly 3 years. We wish him good luck as he heads off to the Foreign Office to learn Korean, before moving out to Asia. Following his departure, Richard Dickinson (email@example.com) will be looking after the compliance courses, including the highly rated, ISTR accredited Biological Safety and Safe Use of Laboratory Gases courses. For the softer skills, Claire Abrams (firstname.lastname@example.org) will be looking after our ever popular Introduction to Drug
Development course as well as other courses in management and people skills.
contact Claire, Richard or any member of the team to find out more.
Alongside our core portfolio of ‘in house’ courses, we offer One Nucleus members an even wider range of training opportunities delivered by Partner organisations such as PTI, who we first introduced in our Spring Newsletter. Excellent discounts are available to One Nucleus members. For more information visit www.pti -global.co.uk/event/onenucleus
We are constantly on the lookout for relevant funding schemes to support our members’ training plans. These are posted on the One Nucleus website www.onenucleus.com/traininggrants.
All of our courses can be adapted and tailored to meet individual objectives, and can be delivered cost effectively in house. Please
Keep checking for opportunities to help you up skill your workforce. Don’t forget that Gold Members receive a 40% discount on One Nucleus courses, Silver 20%, and members of the BIA and CCRA receive 10%.
One Nucleus and Nature Partnership Member benefits – One Nucleus members will benefit from reduced rates for exhibiting at the Naturejobs Career Expo (London or Boston) and additional benefits may be introduced at a later date ‘This partnership will help broaden our view of the life sciences community and provide a platform to share information, feedback and services with each other’s respective audiences’, says Nils Moeller, Global Head of Classified Advertising at Nature Publishing Group.
Naturejobs, the global science career resource and jobs board from Nature, is pleased to announce a new non-commercial partnership with One Nucleus. Both organisations provide key services to the life sciences community and together have a joint objective to benefit this community via: Leadership and engagement – both organisations will work together
One Nucleus members will soon begin seeing editorial content and and engage with the community to jobs from Naturejobs and will be identify and discuss the main issues able to benefit from special discounted rates. facing those working within life sciences and, where possible, For more information: endeavour to provide insight to addressing those issues Naturejobs www.naturejobs.com Naturejobs Career Expo Content sharing – the www.naturejobs.com/careerexpo dissemination of editorial articles, jobs or relevant marketing messages via websites, enewsletters, print and/or events
One Nucleus News
One Nucleus Partner Programme Update For those unfamiliar with the One Nucleus Partner Programme, it offers a fully integrated value proposition to organisations seeking to play an influential and visible role in the development of the life science community. Key Benefits:
Raises the profile of the Partner with key industry partners, potential clients and stakeholders
Provides access to training courses, special interest groups and events at significantly reduced cost to enable staff development
Positions the Partner as a key thought leader in the sector and in the minds of UK and international clients
Offers significant savings on the normal costs and additional benefits only available to One Nucleus Partners via a bespoke Annual Engagement Plan The most recent recruits to Partner status are Nature Publishing Group (NPG), Global Regulatory Services (GRS) and Cambridge IP. Our activities with NPG have to date focused on recruitment via NatureJobs, with plans to expand the collaboration to include joint activities around Nature’s SciBX (Science-Business Exchange) publication and ON Helix 2014. Launched ahead of the NatureJobs Careers Expo in London on 19 September 2013, the UK’s largest careers fair for the science community attracting over 1200 attendees, the collaboration will lead into NatureJobs integral role as part of the ‘Talent Lounge’ facility being introduced at Genesis 2013 in December. Benefits to One Nucleus members of NPG joining the Partner
Programme include discounts on events such as the careers expo, linking the recruitment pages on the One Nucleus web site to the Nature web site, dissemination of news from One Nucleus and our members via NatureJobs partner pages, and engagement of NPG editorial and recruitment experts in our networking events, life science leadership series and larger conferences.
Cambridge IP (Cambridge Intellectual Property Ltd) is the global innovation and intellectual property consultancy.
a One Nucleus Partner, Cambridge IP offers our members significant savings on their range of patent and IP related services including IP Landscapes, IP strategy consulting, innovation management consulting, Freedom to Operate services,
‘You may notice a trend in the above engagement of the new Partners in the area of training and recruitment. This is not a simple twist of fate, but recognition that One Nucleus can play an active role in enabling the best life science talent to be nurtured and networked in the surrounding eco-system’. Tony Jones, One Nucleus GRS has engaged as a Partner of One Nucleus to further raise their profile and increase awareness of their broad advisory role in the regulation of medicines and healthcare technologies. Known for their expertise in areas where regulations are new or in their infancy, GRS pride themselves on their communication with the regulators and payers in order to assist life science companies maximise their advances. Through an innovative collaboration under the Partner Programme, One Nucleus will be launching a new training course entitled ‘An Introduction to Regulation in New Medicines and Healthcare Products’ in the coming months. The course content will be developed and delivered by GRS, enabling our members to provide their staff with a firm understanding of the core business. On-going access to insights from GRS will be available to our members via the Ask One Nucleus dashboard.
patentability searching and patent search training.
will be working with Cambridge IP to provide an ‘Introduction to IP’ course for our members as part of our training portfolio, with Cambridge IP becoming an Approved Adviser for IP Strategy online at Ask One Nucleus. You may notice a trend in the above engagement of the new Partners in the area of training and recruitment. This is not a simple twist of fate, but recognition that One Nucleus can play an active role in enabling the best life science talent to be nurtured and networked in the surrounding eco-system. Access to these new Approved Advisors, in addition to the existing Partner Portfolio of Pharma, Innovation Centres, Science Parks, Technology Transfer, Inward Investment and Publishing Houses creates an ideal mix of stakeholders to enable our sector. For more information contact email@example.com
One Nucleus News
Genesis Conference 2013: Where Scientific, Economic and Healthcare Success Converge
Location, Location, Location Creating an efficient and dynamic conference in central London, now in its thirteenth year the annual Genesis Conference was established to provide a complementary forum to the plethora of bio-partnering, investment and policy-led events in the life science sector calendar Biotech Showcase, JP Morgan, BioEurope, ChinaBio, BIO Investor Forum, BIO and BioEquity to name a few. As one would expect, many of these global events take place in key international locations, however few take part at the heart of a capital city, where R&D scientists, financial and deal making executives and Government policymakers not only rub shoulders, but are trained and network. Genesis is one such conference, located in Westminster, next door to Parliament and a stone’s throw from three of the World’s top medical teaching and research centres, and playing neighbour to one of the most globally successful financial centres. One should also not forget,
that in an age of convergence in healthcare delivery where mobile apps, big data and electronic patient records play an ever increasing role, London also provides a leading ICT sector base with which the BioPharma and Healthcare industry can interface daily. Highlights of Genesis 2013
700 delegates from across the life sciences spectrum
Opening Plenary Session
Who’s Leading Who? The programme at Genesis this year will provide delegates the chance to engage in debate around their hopes and fears for the sector and how opportunities can be grasped. The main day will commence with a breakfast policy session, led by the BioIndustry Association (BIA) setting out the way in which they are working with One Nucleus, Bionow and BiopartnerUK to develop a compelling Life Science Manifesto ahead of the next parliamentary elections.
12 tailored breakout leadership
The following Plenary Session of key opinion leaders will include Louise Wood (Department of The SCRIP – One Nucleus Health), Sir Salvador Moncada Plenary Debate (UCL), and Roel Bulthuis (Merck Online 1-2-1 partnering facility Serono Ventures), and who will provide insight into the interactions Careers, recruitment and training between the public sector payers, strategy hub academia, industry and corporate venture funds, and how these will 70 Exhibitors enable improvements in healthcare outcomes on a global scale. The Pre-Genesis Seminar, session will be completed by Mike BioNewsRound Award Final and Ward presenting new data from Welcome Reception on 11 Informa Group’s suite of products December 2013 describing the state of the industry and what we might expect in the next twelve months. sessions
The single stream format will return to in the afternoon, taking the form of a Plenary Debate. In BBC Question Time format and chaired by John Hodgson (SCRIP Intelligence), a panel of experts will debate The Industry in 2018: Predictions, Hopes and Fears. We are delighted to confirm panellists including George Freeman MP, the Government’s Life Science Champion, Shaun (Continued on page 31)
One Nucleus News
Mike Ward, Global Director of Content, SCRIP speaking at Genesis 2012
and innovations led by TranScrip Partners; and a UKTI Showcase highlighting strengths of the UK offer. The international faculty of 60+ speakers, including executives from academia, biotech and pharma Industries, expert advisers and regulators, will provide insights and debate that will enable all delegates to engage, learn, and depart better equipped to perform their day jobs. Meeting the Right Targets
are arranged, thus providing an ideal springboard for future developments. The partnering facility is located within the UKTI International Zone where key market and geographical Commercial Officers of UK Trade & Investment from over 20 countries are available to share data on territories of high potential. Further details on which Commercial Officers will be attending are available on the conference website and via the online partnering system. Since the introduction of a partnering facility to Genesis in 2009 there has been a consistent rise in the number of face-to-face meetings scheduled, with 2012 delivering almost 1,000 connections over the course of the day. Pre-Genesis Seminar, BioNewsRound Award and Welcome Reception We are delighted to be returning to Canada House for a pre-conference afternoon and evening session. Genesis delegates are invited, however please note availability is limited and subject to capacity at time of reservation. The afternoon will feature seminars from: Andrew Casey, CEO of BioteCANADA, describing the strengths and collaborative opportunities in the Canadian Life Sciences sector; Chris Farmakis of GLE, who will detail the funding and support programmes available
David Phillips, Partner, SR One
It is human nature to want to be as efficient as possible in our various roles. The immense growth of the bio-partnering conference capacity is testament to both the need for collaboration and deals within the life sciences industry as well as the Grady, VP of Strategic Partnering and Business Development at desire to network. Even with highly AstraZeneca, David Philips, efficient partnering facilities, Partner at SROne, and Mike Ward, selecting the right targets is still a challenge in this era of converging Head of Content, Informa. technologies. The lighter touch Breakout Leadership Sessions approach to partnering at Genesis The middle section of the complements the agenda and conference programme will include delegate mix and is designed to sessions focusing on the maximise the networking technologies and strategies behind opportunity in order to gain innovative product development. knowledge and insight. The added Each session will feature two efficiency of pre-scheduled 15 keynote speakers followed by a minute 1-2-1 meetings via Q&A panel discussion with Howdi ensures high quality additional experts from the field. contacts are met in order to share insights, feasibility of working with Sessions will include Managing Big new partners or solution providers Data in R&D with John Parkinson is tested and follow up meetings (MHRA) and Kat Zarychta (HistoIndex); Biomarkers in Oncology: Lessons from other Therapeutic Areas with Richard Pither (Cytox) and Hanns-Georg Klein (IMGI Labs, Munich); Imaging in CNS with Kevin Cox (Imanova) and John Oâ€™Brien (University of Cambridge); Antibody-Based Therapeutics with Martin Welschoff (Opsona Therapeutics) and Matthias Grossmann (Parexel); Natural Product Development with Andrew Casey (BioteCanada) and Meredith Lloyd-Evans (BioBridge); 4 Case Study Deals selected and analysed by SCRIP Intelligence; 2 Pharma Partnering Showcase sessions looking at recent trends
(Continued on page 32)
One Nucleus News
Itâ€™s a People Thing! We all know that success comes through building the right teams, yet do we pay sufficient attention to ensuring the training, recruitment and career path strategies across our sector are fit for purpose? This yearâ€™s exhibition hall will feature a physical hub where delegates can seek 1-2-1 expert advice on matters relating to personal and company development through talent management.
The evening session will be dedicated to the theme of selling the sector to the wider community, a topic often overlooked at conferences that focus on product development, finance and deal making. It is vital that the life
The SCRIP One Nucleus Debate 2012
Our most recent recruit to the One Nucleus Partner Programme, to all companies raising capital and science and healthcare sectors have Nature Publishing Group, will be partnering on the international on hand to discuss scientific effective engagement with the stage; and Jo Pisani, Partner, recruitment trends, with colleagues public, patient groups, and Price Waterhouse Coopers, who will emerging bright sparks in science. from the editorial side of MacMillan share insights from the November Press, strategies for successful By showcasing good practice in Pharma Integrates conference on public engagement, the session will science writing and publication. emerging strategies between highlight the benefits in terms of Pharma, CROs and biotechs in the Pharma Training International, better healthcare outcomes in pursuit of product and commercial another One Nucleus Partner, will general. success. be on hand to discuss training Celebrating success and enthusing needs and strategies. Completing We will also hear from guest an audience are the main the human capital jigsaw a number objectives of any awards ceremony. speaker Ricky Martin, founder of of our executive search members Hyper Recruitment Solutions and Alongside this, showcasing great winner of the BBC Apprentice 2012, will be very happy to advise on things builds investor and wider on what it takes to attract top class recruitment and retention stakeholder confidence, which in strategies for emerging life science talent into the sector through turn generates investment and companies. education and careers advice, as ultimately results in even more well as how to appeal to nonsuccess to celebrate! The 2013 For more information contact specialist business leaders such as BioNewsRound Award final will firstname.lastname@example.org Lord Alan Sugar to back the sector follow the popular format as a business opportunity. introduced last year, where selected finalists are given just 4.5 minutes to describe why their milestone announcement is significant to their company, the sector, and patients. A small panel of expert judges will select the winner, to be announced during the Welcome Reception, based upon their assessment of the significance of the announced development and the quality of the presentation.
One Nucleus News
One Nucleus Insights
One of the benefits of being the largest life science membership group in Europe is security in the knowledge that our network has some of the best placed thought leaders to address current sector challenges. There is of course never a ‘one size fits all’ or a simple answer to many of the challenges of, for example, raising capital or developing and maintaining optimal R&D facilities.
from an AIM listing being between £3M and £30M; allocation of follow on capital, for example, Sareum and e-Therapeutics; measures taken by the Government in response to LSE group lobbying to incentivise AIM investors - (removal of stamp duty and a recommendation to engage early with AIM Nominated Advisers (Nomads)).
The One Nucleus Insights initiative has been developed to assemble small, focused groups of experts from our membership and wider network to debate current challenges and possible solutions. Far from being discrete exercises, the round table discussions and subsequent publication of the findings are intended to stimulate debate within our community and feed into later event agendas.
The findings whilst disseminated as a white paper also informed the development of the agenda for the 25 September 2013 Life Science Leadership Seminar on Investment Strategies in Life Sciences, where London Stock Exchange and FinnCap were again taking part.
Imperial Incubator hosted a round table breakfast on Provision of Commercial R&D Space in The first ON Insight on London London in July. The event was Stock Exchange Life Science prompted by the on-going IPOs – Renewed Throughput challenges in creating and and Investor Participation maintaining commercial facilities in centred on a lunch discussion London that are both fit-forhosted by Mills & Reeve in June at purpose and affordable for the Mills & Reeve Cambridge emerging life science companies. A offices . The leading theme of the number of key points and discussion was the opportunity for recommendations were raised that life science companies, including included: the pressures faced by drug discovery, medical technology, space providers due to the limited diagnostics and Pharma services, to pipeline of new companies being raise development capital from the created; academic space demands public markets in London. Key at host colleges; and the changing discussion points included: needs of modern R&D companies. Cambridge Cognition and Sphere On the flip side, companies raised Medical Holdings as recent success concerns about the high business stories; the typical sums raised operating costs in London, lack of
shared facilities to increase capital efficiency and low availability of grow–on space in suitable locations. A number of recommendations were made by the group such as lobbying the London Mayor to reduce business rates, greater coordination across the large university centres to access shared equipment facilities and services, and to engage with major developments such as those in Albert Dock to ensure life sciences is a well-represented sector for tenancy. The findings fed nicely into the September BioWednesday at Queen Mary Innovation Centre where Adrian Gainer of HOK presented the findings of their research (primarily US) on the current trends in R&D facility design and how the occupiers are using the space. The presentation was the preface to a wider debate on how innovation centres could provide a higher proportion of open, shared spaces to encourage collaboration between tenants. The overriding conclusion was that a new approach to innovation centre financing is required where both capital and revenue expenditure in the early years allows for the recruitment of the ‘right mix’ of tenants. This in contrast to the current structures that place emphasis on short term occupancy rates from the start in order to create revenue streams. The debate continued at the most recent breakfast round table, which was hosted by London BioScience Innovation Centre, on 9 October 2013. For more information contact email@example.com
One Nucleus News
On Hub - Our New Service London & Partners, London Bridge, London www.londonandpartners.com
events, food, drinks, WiFi, car parking and more
to business, students and visitors. The team works in partnership with
life science executives to access
organisations across the world to
meeting space and office facilities
achieve the goal – that London is
at various life science hubs. Here
recognised as the best big city on
they can, for example, use WiFi and Earth. refreshment whilst meeting business colleagues by pre-
Contact: Warren Bartlett firstname.lastname@example.org
interest when travelling.
BioPark, Welwyn Garden City
Facilities are available to holders of
Located close to the heart of
The card is free to life science executives upon registration with
London's biomedical technology
Network with other Allegiance members at exclusive events
Easy booking, with our dedicated Allegiance portal and
Simple to claim – simply present your Allegiance card at check out
Free to join and easy to save -
specialist facilities and support for
number when you book
Each card will be for exclusive
and the development of new
Hub locations will be listed on
Save money on business and
just quote your Allegiance card
community, BioPark provides bioscience and health technology
use of the holder and carry a
More than 100 hotels across the
24/7 reservations line
arrangement or to share a common
an ON Hub membership card.
and 5% off meetings and
promotional organisation for
initiative creates an opportunity for
business services, have coffee and
10% saving on accommodation
London & Partners, the official London, attracts and delivers value A newly launched One Nucleus
benefits are as follows:
businesses, encouraging growth products and technologies Contact: Stacey O’Flaherty email@example.com
the One Nucleus website along
A dedicated meetings and events facilitator to help you find your perfect venue
Plus– Allegiance members can now enjoy 5% off at LivingWell Health Clubs too!
with contact details
ON Hub members can contact an individual hub in advance to arrange access. Specific terms and conditions may apply that differ from hub to hub
Access to a hub will require one additional form of photo id to gain access to facilities
Hilton Doubletree Allegiance Programme
Life Sciences Hub Wales
An iconic building in Cardiff Bay will
create the focal point for Life
Sciences in Wales The Hub is the
Allegiance is a new programme
place to meet people who know
from our Support Supplier, Hilton Doubletree, crafted specifically for SME businesses, and offering savings when visiting any of the
Participating Hubs One Nucleus, Granta Park, Cambridge www.onenucleus.com
about Life Sciences in Wales and internationally The Hub will have great facilities for meetings, networking and events The Hub will
Hilton Worldwide portfolio.
be the go to place for life sciences
Contact: Register online at http://
grow To be launched on the 5
hiltonsme.hiltonbusinessonline.com /join-allegiance adding (One
Contact: Polly Pollock
Nucleus) to your company name
on the on line registration form Joining Allegiance is free and
businesses to start, develop and March at BioWales. For more information about ON Hub please contact firstname.lastname@example.org
One Nucleus News
Promotional Opportunity: One Nucleus Members’ Directory 2014 – Don’t Miss Out!
Don’t forget to update your company profile and take advantage of the different marketing and promotional opportunities in the One Nucleus Members’ Directory 2014.
life science conferences, networking exhibitions and workshops, training courses, dates for your diary, special interest groups, European activities and strategic relations with the US clusters.
Used extensively as a reference source by members and key stakeholders at a national and international level, the Directory is a great platform to raise your organisation’s profile and brand.
The Directory will be distributed to every member, stakeholder and partner as well as being used to promote the members and One Nucleus at trade shows, conferences and events. There’ll also be an electronic version, emailed to our 10,000 international
It also includes all the information on our services and collaborations,
contacts and available to download from our website. Our partner for the directory is Publishing Events, so you’ll be hearing from them over the next few weeks if you haven’t already. If you’d like to find out more about the opportunities available in the directory, please contact Ben Scott on 020 7841 5962 or email@example.com
One Nucleus News
One Nucleus Purchasing Scheme Earlier in the year the Purchasing Consortium signed a 3 year extension with Harts Business Solutions as the Preferred Supplier for Stationery and IT Consumables. Andrew Turnbull, Sales and Marketing Director, expressed his delight to be continuing to work with One Nucleus. ‘Harts Team work very hard at building close relationships with the Consortium members to not only offer competitive core prices, but also better understand their specific needs. I believe there is more to being a Preferred Supplier than simply providing a core list, I like to think we are a trusted partner delivering a comprehensive business solution for all One Nucleus members.’
partnership and working to bring One Nucleus members the choice and convenience of the Fisher Scientific range at great prices.’
Andrew Porter, Laboratory Relocation Specialists, is the latest The PSA for Molecular Biology, Cell Support Supplier to be added to the Biology and Tissue Culture products growing number of suppliers that currently with Sigma Aldrich will be are offering discounts to our tendered in the New Year, with the members. For the full list please new contract starting on the 1 April see the Purchasing pages on the 2014. One Nucleus website or contact Richard at firstname.lastname@example.org or 01223 896453.
This month the Purchasing Consortium voted to extend its Preferred Supplier Agreement (PSA) with Fisher Scientific for Laboratory Consumables, Chemicals and Low Value Apparatus for a further two years. Martin Reilly, Regional Manager, Fisher Scientific, thanked the consortium for the extension to the end of 2015, saying, ‘We look forward to continuing our
Facilities Management Richard Dickinson, Director of Specialist Services, One Nucleus
Don’t forget that One Nucleus offers Facilities Management consultancy to members at a discounted rate. Richard Dickinson (email@example.com or 01223 896453), One Nucleus's Director of Specialist Services, has over 15 years’ experience as a Facilities Manager and has worked for more than 20 years in the life science sector. Richard provides project management for office and laboratory fit-outs and can advise on equipment service contracts,
Consultancy Day Rate
maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. Currently consulting at Cantab Biopharmaceuticals, Fahy Gurteen Laboratories and Pathology Diagnostics, Richard has previously consulted for a number of One Nucleus members on various projects including Astex Therapeutics, Babraham Bioscience Technologies, Zoragen and Spirogen. Richard can provide help by phone or email as well as providing full onsite consultancy.
One Nucleus News
New Members Inspirexe Ltd Xintera Ltd HAhydra Technologies Ltd
Pharmaterials Ltd RxCelerate Ltd Euro Japan Marketing
Ltd Micron Research Ltd WilmerHale LLP Actigen Ltd Geneix Shionogi Ltd Babraham Commercialisation Services Ltd Avergen Ltd Sphere Fluidics Ltd Nomura Code Securities Poiesis Therapeutics Link China Pharma
Ltd Walnut Medical
BlueGnome Ltd Puridify Ltd AQIX Ltd Harlow District Council Ball and Company Ltd Origimm e.U LE Executive Resourcing Ltd Areteva Ltd Echowave Healthcare Ltd London Research Institute Cancer Research UK Biotransys Ltd Real Pharma Helminthic Therapy
Recruitment Speid & Associates King's College London Work Area Ltd
HOK Neuro-Bio Ltd Illingworth Research Ltd Bactevo Ltd LV Scientific Ltd SYNthesis med chem MedGenesis Ltd Psimonix Ltd Yorkshire Biotec Ltd Gel Repairer Ltd TCF Consulting SPRL Cambridge Epigenetix Ltd Valevia UK Ltd Kent Science Park
One Nucleus Events Date
16 Oct 13
Stevenage Bioscience Catalyst
6 Nov 13
14 Nov 13
Life Science Leadership Seminar
Charles Russell, London
27 Nov 13
12 Dec 13
QEII Conference Centre, London
8 Jan 14
29 Jan 14
5 Feb 14
BioWednesday with Deloitte
Life Science Leadership Series
5 Mar 14
19 Mar 14
Media Partners 19 Mar 14